Table S2B.
Results of cost model: asthma-related medical costs
| Variable | Parameter estimate | 95% CI | P value | |
|---|---|---|---|---|
| Fluticasone-salmeterol (1 = yes) | −0.6675 | −0.8566 | −0.4783 | <0.0001 |
| Age (continuous) | 0.0622 | 0.0170 | 0.1075 | 0.0071 |
| Male (1 = yes) | −0.2849 | −0.4582 | −0.1117 | 0.0013 |
| Midwest region* (1 = yes) | 0.0881 | −0.1113 | 0.2875 | 0.3864 |
| South region* (1 = yes) | 0.0970 | −0.2215 | 0.4155 | 0.5505 |
| Charlson index in pre-index period (continuous) | 0.3038 | 0.2104 | 0.3972 | <0.0001 |
| Presence of allergic rhinitis (1 = yes) | 0.0609 | −0.1100 | 0.2319 | 0.4849 |
| Number of SABA canisters (continuous) | 0.0306 | −0.0624 | 0.1235 | 0.5192 |
| Number of OCS prescriptions (continuous) | −0.0079 | −0.1073 | 0.0916 | 0.8767 |
| Number of ICS canisters (continuous) | 0.0041 | −0.1002 | 0.1083 | 0.9388 |
| Number of hospital/ED visits for respiratory-related conditions (continuous) | 0.4177 | 0.2786 | 0.5568 | <0.0001 |
| Respiratory-related medical costs (natural log) | 0.1075 | 0.0632 | 0.1518 | <0.0001 |
| Asthma-related pharmacy costs (natural log) | 0.0091 | −0.0412 | 0.0594 | 0.7227 |
Note:
*
Reference group, East region.
Abbreviations: ED, emergency department; ICS, inhaled corticosteroid; OCS, oral corticosteroid; SABA, short-acting beta agonist; CI, confidence interval; HR, hazards ratio.